Skip to main content
main-content
Top

09-09-2021 | COVID-19 | News

News in brief

Favorable outcomes in pregnant women with RMDs and COVID-19

Author:
Claire Barnard

medwireNews: Preliminary study results from the COVID-19 Global Rheumatology Alliance suggest that pregnant women with rheumatic and musculoskeletal diseases (RMDs) have generally favorable outcomes following SARS-CoV-2 infection.

Although the study was limited by small patient numbers, the findings “provide cautious optimism for pregnancy outcomes for women with rheumatic disease,” say Philip Robinson (Royal Brisbane & Women’s Hospital, Queensland, Australia) and co-authors.

They analyzed data from 39 women (average age 33 years) included in the registry in March 2020–January 2021. The most common RMDs were rheumatoid arthritis (n=9) and systemic lupus erythematosus (n=9); most were in remission (33.3%) or had minimal/low disease activity (46.2%).

Robinson et al report that 10 women were hospitalized, but only two required supplemental oxygen and there were no deaths. Among the 22 with pregnancy outcome data available, 72.7% had a term birth. There were 10 cesarean deliveries, eight vaginal deliveries, two not delivered at the time of reporting, one miscarriage, and one termination.

While these data suggest favorable outcomes in this patient group, the study was “purely descriptive,” and further evaluations will be carried out “to inform disease and pregnancy outcomes for women with rheumatic diseases who are pregnant and have COVID-19,” write the researchers in The Journal of Rheumatology.

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group

9 September 2021: The coronavirus pandemic is affecting all healthcare professionals across the globe. Medicine Matters’ focus, in this difficult time, is the dissemination of the latest data to support you in your research and clinical practice, based on the scientific literature. We will update the information we provide on the site, as the data are published. However, please refer to your own professional and governmental guidelines for the latest guidance in your own country.

J Rheumatol 2021; doi:10.3899/jrheum.210480

COVID-19 vaccination in patients with rheumatic diseases

Get answers to key questions with recommendations from professional organizations

Anifrolumab for the treatment of lupus

Perspective on the approval of anifrolumab and the importance of endpoints in lupus trials.

JAK inhibitor safety

Data summary and expert discussion on the potential risks associated with JAK inhibitors.